An Evaluation of Drug-Drug Interaction Alerts Produced by Clinical Decision Support Systems in a Tertiary Hospital

被引:2
|
作者
Alanazi, Abdullah [1 ,2 ]
Alalawi, Wejdan [3 ]
Aldosari, Bakheet [1 ,2 ]
机构
[1] King Saud Bin Abdulaziz Univ Hlth Sci, Hlth Informat, Riyadh, Saudi Arabia
[2] King Abdullah Int Med Res Ctr, Res, Riyadh, Saudi Arabia
[3] Prince Mohammed Bin Abdulaziz Hosp, Nursing, Medina, Saudi Arabia
关键词
computerized provider order entry (cpoe); adverse drug events; drug interactions; clinical decision support systems (cdss); ddi alerts; PHYSICIAN ORDER ENTRY; EVENTS; RATES;
D O I
10.7759/cureus.43141
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Drug -drug interactions (DDIs) have the potential to harm patients. Hence, DDI alerts are meant to prevent harm; as a result, their usefulness is reduced when most alerts displayed to providers are ignored. This study aims to explore the rates and reasons for overriding alerts of DDI. Methods This is a retrospective study of DDI alert overrides that occurred between January 2020 and December 2020 within the inpatient medical records at a tertiary hospital, Medina City, Kingdom of Saudi Arabia. Results A total of 7,098 DDI alerts were generated from inpatient settings, of which 6,551(92.2%) were overridden by the physicians at the point of prescribing. "Will Monitor as Recommended" (33%) was the most common reason for the override, followed by 'Will Adjust the Dose as Recommended (27.1%)," "The Patient Has Already Tolerated the Combination" (25.7%), and "No Overridden Reason Selected" (13.0%). Discussion The DDI alert overriding is still high and is comparable to other studies. However, this study reveals that physicians are ready to deal with the consequences of around 58% of DDI alerts. Additionally, 13% of physicians were not willing to report the reason for overriding. This indicates an urgent need to review and restructure the DDI alert system. Conclusion The DDI alert override rates are high, and this is undesirable. It is recommended to revise the DDI alert system. Future studies should dig deep for real reasons for overriding and seek inputs from all stakeholders, including developing actionable metrics to track and monitor DDI alerting system.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] Management of Drug-Drug Interaction Alerts for Clinical Decision Support in Outpatients
    Su, Chien Hao
    Hsu, Chien Ning
    Tsai, Shu Chen
    Wang, Yu Chin Lily
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 299 - 299
  • [2] Customizing clinical decision support to prevent excessive drug-drug interaction alerts
    Horn, John R.
    Hansten, Philip D.
    Osborn, Jacqueline D.
    Wareham, Pamela
    Somani, Shabir
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2011, 68 (08) : 662 - 664
  • [3] Recommendations to improve the usability of drug-drug interaction clinical decision support alerts
    Payne, Thomas H.
    Hines, Lisa E.
    Chan, Raymond C.
    Hartman, Seth
    Kapusnik-Uner, Joan
    Russ, Alissa L.
    Chaffee, Bruce W.
    Hartman, Christian
    Tamis, Victoria
    Galbreth, Brian
    Glassman, Peter A.
    Phansalkar, Shobha
    van der Sijs, Heleen
    Gephart, Sheila M.
    Mann, Gordon
    Strasberg, Howard R.
    Grizzle, Amy J.
    Brown, Mary
    Kuperman, Gilad J.
    Steiner, Chris
    Sullins, Amanda
    Ryan, Hugh
    Wittie, Michael A.
    Malone, Daniel C.
    JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2015, 22 (06) : 1243 - 1250
  • [4] Evaluation of Contraindicated Drug-Drug Interaction Alerts in a Hospital Setting
    Hatton, Randy C.
    Rosenberg, Amy F.
    Morris, Candice T.
    McKelvey, Russell P.
    Lewis, James R.
    ANNALS OF PHARMACOTHERAPY, 2011, 45 (03) : 297 - 308
  • [5] Comment: Evaluation of Contraindicated Drug-Drug Interaction Alerts in a Hospital Setting
    Horn, John R.
    Hansten, Philip D.
    ANNALS OF PHARMACOTHERAPY, 2011, 45 (06) : 826 - 826
  • [6] Evaluation of Clinical Relevance of Drug-Drug Interaction Alerts Prior to Implementation
    Meslin, S. M. M.
    Zheng, W. Y.
    Day, R. O.
    Tay, E. M. Y.
    Baysari, M. T.
    APPLIED CLINICAL INFORMATICS, 2018, 9 (04): : 849 - 855
  • [7] SFINX—a drug-drug interaction database designed for clinical decision support systems
    Ylva Böttiger
    Kari Laine
    Marine L. Andersson
    Tuomas Korhonen
    Björn Molin
    Marie-Louise Ovesjö
    Tuire Tirkkonen
    Anders Rane
    Lars L. Gustafsson
    Birgit Eiermann
    European Journal of Clinical Pharmacology, 2009, 65 : 627 - 633
  • [8] Override rate of drug-drug interaction alerts in clinical decision support systems: A brief systematic review and meta-analysis
    Felisberto, Mariano
    Lima, Geovana dos Santos
    Celuppi, Ianka Cristina
    Fantonelli, Miliane dos Santos
    Zanotto, Wagner Luiz
    de Oliveira, Julia Meller Dias
    Mohr, Eduarda Talita Bramorski
    dos Santos, Ranieri Alves
    Scandolara, Daniel Henrique
    Cunha, Celio Luiz
    Hammes, Jades Fernando
    da Rosa, Julia Salvan
    Demarchi, Izabel Galhardo
    Dalmarco, Eduardo Monguilhott
    HEALTH INFORMATICS JOURNAL, 2024, 30 (02)
  • [9] SFINX-a drug-drug interaction database designed for clinical decision support systems
    Bottiger, Ylva
    Laine, Kari
    Andersson, Marine L.
    Korhonen, Tuomas
    Molin, Bjorn
    Ovesjo, Marie-Louise
    Tirkkonen, Tuire
    Rane, Anders
    Gustafsson, Lars L.
    Eiermann, Birgit
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (06) : 627 - 633
  • [10] Consensus Recommendations for Systematic Evaluation of Drug-Drug Interaction Evidence for Clinical Decision Support
    Scheife, Richard T.
    Hines, Lisa E.
    Boyce, Richard D.
    Chung, Sophie P.
    Momper, Jeremiah D.
    Sommer, Christine D.
    Abernethy, Darrell R.
    Horn, John R.
    Sklar, Stephen J.
    Wong, Samantha K.
    Jones, Gretchen
    Brown, Mary L.
    Grizzle, Amy J.
    Comes, Susan
    Wilkins, Tricia Lee
    Borst, Clarissa
    Wittie, Michael A.
    Malone, Daniel C.
    DRUG SAFETY, 2015, 38 (02) : 197 - 206